Loading
CP
Callisto Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CERRONE GABRIEL, was filed 17 Nov 2010.
Callisto Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Callisto Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. No insider at Callisto Pharmaceuticals Inc has published a filing in the past twelve months. The most recent one dates from 22 January 2013.
Looking back to 2006, when coverage begins, insiders filed 2 purchases and 7 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
16
Thresholds
n/a
Buy Volume
€3,278
2 ops. · all time
Sell Volume
€16,026
7 ops. · all time
Financial data
as of FY 2011FY ended December 2011 · cache
Income statement
Net income-6.1M
Last declaration on 22 January 2013
Declarations16 total
113,636 sharesCommon StockSEC:0001104659-13-003846:0
113,636 sharesCommon StockSEC:0001104659-13-003845:0
21,891,922 sharesCommon StockSEC:0001104659-13-003848:0
2,184,672 sharesCommon StockSEC:0001104659-13-003842:0
147,245 sharesCommon StockSEC:0001104659-13-003843:0
12,000,000 shares0Common StockSEC:0001104659-12-022036:0
12,935 sharesCommon StockSEC:0001104659-10-058934:0
Canonical exit: 13 Feb 2011 (T+90)
5,000 shares@ US$0.216Common StockSEC:0001104659-10-002258:0
25,000 shares@ US$0.215Common StockSEC:0001104659-10-002258:1
25,000 shares@ US$0.24Common StockSEC:0001104659-10-002258:2
25,000 shares@ US$0.245Common StockSEC:0001104659-10-002258:3
5,000 shares@ US$0.245Common StockSEC:0001104659-10-002258:4
500 shares@ US$0.245Common StockSEC:0001104659-10-002258:5
14,500 shares@ US$0.22Common StockSEC:0001104659-10-002258:6
12,500 shares@ US$0.49Common StockSEC:0001104659-07-076891:0
5,000 shares@ US$0.84Common StockSEC:0001104659-06-056515:0
Canonical exit: 19 Nov 2006 (T+90)
16 of 16 declarations
About Callisto Pharmaceuticals Inc
Callisto Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for cancer-related diseases and gastrointestinal disorders. It is listed on the NASDAQ under the symbol CLSD.
